TKIs (EGFR VEGF BTK etc.)

Delve into the world of TKIs (EGFR VEGF BTK etc.) in China’s pharmaceutical industry. Fineline Info & Tech provides reliable data, news, and insights on TKIs (EGFR VEGF BTK etc.) to help you navigate complexities with precision and clarity. Stay informed and enhance your decision-making at flcube.com.

Atavistik Bio Strikes CVRM Collaboration with Roche – USD 70 Million Upfront, up to USD 1.9 Billion in Milestones for Allosteric Small‑Molecule Discovery
CompanyDeals

Atavistik Bio Strikes CVRM Collaboration with Roche – USD 70 Million Upfront, up to USD 1.9 Billion in Milestones for Allosteric Small‑Molecule Discovery

Atavistik Bio announced a strategic research collaboration with Roche Holding AG (SWX: ROP; OTCMKTS: RHHBY) to discover and develop novel small molecule therapies targeting multiple targets in cardiovascular, renal, and…

HUTCHMED Initiates Phase Ia Global Trial of HMPL-A830 – First‑in‑Class KRAS‑Payload Antibody‑Targeted Conjugate Licensed to GSK for up to USD 1.295 Billio

HUTCHMED Initiates Phase Ia Global Trial of HMPL-A830 – First‑in‑Class KRAS‑Payload Antibody‑Targeted Conjugate Licensed to GSK for up to USD 1.295 Billion

FDA Approves AbbVie's Tavapadon as Juvmo for Parkinson's Disease – Once‑Daily Dopamine Mimetic Joins $8.7 Billion Cerevel Portfoli

FDA Approves AbbVie’s Tavapadon as Juvmo for Parkinson’s Disease – Once‑Daily Dopamine Mimetic Joins $8.7 Billion Cerevel Portfolio

Empowering Chinese Pharma’s Global Expansion

Leverage premier media reach to connect your pipeline with global partners. Contact us to drive your international growth today.
Explore Now
Allist Pharmaceuticals' NDA Accepted by China's CDE for Furmonertinib in Adjuvant NSCLC – Third‑Generation EGFR‑TKI Targets Post‑Resection Patients with Exon 19 Deletion or L858R Mutations
CompanyDrug

Allist Pharmaceuticals’ NDA Accepted by China’s CDE for Furmonertinib in Adjuvant NSCLC – Third‑Generation EGFR‑TKI Targets Post‑Resection Patients with Exon 19 Deletion or L858R Mutations

Nuvation Bio Secures FDA sNDA Approval for IBTROZI® (Taletrectinib) – Updated Label Reports Longest Median DOR Among Approved ROS1 TKIs in TKI‑Naïve ROS1‑Positive NSCLC
CompanyDrug

Nuvation Bio Secures FDA sNDA Approval for IBTROZI® (Taletrectinib) – Updated Label Reports Longest Median DOR Among Approved ROS1 TKIs in TKI‑Naïve ROS1‑Positive NSCLC

GSK's ROS1 Inhibitor Jideytro (Zidesamtinib) Posts 94 % Response Rate in TKI‑Naïve ROS1‑Positive NSCLC – Phase I/II ARROS‑1 Delivers Durable Responses With 90 % 12‑Month PFS
CompanyDrug

GSK’s ROS1 Inhibitor Jideytro (Zidesamtinib) Posts 94 % Response Rate in TKI‑Naïve ROS1‑Positive NSCLC – Phase I/II ARROS‑1 Delivers Durable Responses With 90 % 12‑Month PFS

CompanyDrug

Fosun Pharma’s luvometinib Wins NMPA Approval for NF1-Associated Plexiform Neurofibromas in Adults

CompanyDrug

TYK Medicines’ Asandeutertinib Wins NMPA Conditional Approval for EGFR-Mutant NSCLC with CNS Metastases

CompanyDrug

Sino Biopharma’s benmelstobart-anlotinib Combo Wins NMPA Nod for First-Line sq-NSCLC

CompanyDeals

TYK Medicines and Qilu Pharmaceutical Forge Strategic Partnership for EGFR-TKI TY-9591 with $2.4B Deal

CompanyDeals

Dizal Pharmaceutical Secures $1.5 Billion Global Licensing Deal with AstraZeneca for Sunvozertinib in EGFR Exon20ins NSCLC

Show More